Abstract Number: 13L • 2016 ACR/ARHP Annual Meeting
Low-Dose IL-2 Therapy in Refractory SLE: Results from Single Center Phase I/IIa Clinical Trial
Background/Purpose: Interleukin-2 (IL-2) is crucial for the growth and survival of regulatory T cells (Treg), and thus for the control of autoimmunity. In previous studies…